U.S. patent application number 16/448588 was filed with the patent office on 2019-10-24 for intraocular delivery of bioactive molecules using iontophoresis.
The applicant listed for this patent is KEMIN INDUSTRIES, INC.. Invention is credited to Giovanni Cavallo, Diogo de Sousa Martins, Fulvio Foschini, Pierre Roy.
Application Number | 20190321221 16/448588 |
Document ID | / |
Family ID | 56127887 |
Filed Date | 2019-10-24 |
![](/patent/app/20190321221/US20190321221A1-20191024-D00000.png)
![](/patent/app/20190321221/US20190321221A1-20191024-D00001.png)
![](/patent/app/20190321221/US20190321221A1-20191024-D00002.png)
United States Patent
Application |
20190321221 |
Kind Code |
A1 |
de Sousa Martins; Diogo ; et
al. |
October 24, 2019 |
INTRAOCULAR DELIVERY OF BIOACTIVE MOLECULES USING IONTOPHORESIS
Abstract
Iontophoresis, a minimally-invasive methodology that uses a weak
electric current to enhance penetration of ionized molecules into
tissues, was found to be an effective technique for the intraocular
delivery of large bioactive molecules, specifically lutein.
Inventors: |
de Sousa Martins; Diogo;
(Sao Paulo, BR) ; Roy; Pierre; (Paris, FR)
; Cavallo; Giovanni; (Rome, IT) ; Foschini;
Fulvio; (Rome, IT) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
KEMIN INDUSTRIES, INC. |
Des Moines |
IA |
US |
|
|
Family ID: |
56127887 |
Appl. No.: |
16/448588 |
Filed: |
June 21, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14977048 |
Dec 21, 2015 |
10327946 |
|
|
16448588 |
|
|
|
|
62094663 |
Dec 19, 2014 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61F 9/0026 20130101;
A61K 9/0051 20130101; A61K 31/045 20130101; A61N 1/044 20130101;
A61K 31/047 20130101; A61P 27/00 20180101; A61K 31/065 20130101;
A61F 9/0008 20130101; A61K 9/0009 20130101; A61K 9/127 20130101;
A61N 1/303 20130101; A61P 43/00 20180101 |
International
Class: |
A61F 9/00 20060101
A61F009/00; A61P 43/00 20060101 A61P043/00; A61K 9/127 20060101
A61K009/127; A61P 27/00 20060101 A61P027/00; A61K 31/047 20060101
A61K031/047; A61K 31/045 20060101 A61K031/045; A61K 31/065 20060101
A61K031/065; A61K 9/00 20060101 A61K009/00 |
Claims
1. A method of depositing a bioactive molecule in ocular tissues,
comprising the steps of formulating a liposome containing the
bioactive molecule, charging an iontophoresis device with a
composition of the bioactive molecule-containing liposome, applying
the iontophoresis device to the eye of a subject, and operating the
iontophoresis device.
2. The method of claim 1, wherein the bioactive molecule is
selected from the group consisting of carotenoids.
3. The method of claim 2, wherein the carotenoid is selected from
the group consisting of lutein and zeaxanthin.
4. The method of claim 1, wherein the liposome has a positive zeta
potential.
5. A method of treating, ameliorating or preventing an ocular
disease or dysfunction, comprising the steps of formulating a
liposome containing the bioactive molecule, charging an
iontophoresis device with a composition of the bioactive
molecule-containing liposome, applying the iontophoresis device to
the eye of a subject, and operating the iontophoresis device.
6. The method of claim 5, wherein treating, ameliorating or
preventing an ocular disease or dysfunction is delaying the onset
of age-related macular degeneration.
7. The method of claim 5, wherein treating, ameliorating or
preventing ocular disease or dysfunction is preventing or delaying
the progression of age-related macular degeneration.
8. The method of claim 5, wherein the ocular disease or dysfunction
is age-related macular degeneration.
9. The method of claim 5, wherein the ameliorating or preventing of
an ocular disease or dysfunction comprises carrying out the method
in healthy subjects.
Description
[0001] This application is a continuation of U.S. patent
application Ser. No. 14/977,048, filed Dec. 21, 2015, and entitled
INTRAOCULAR DELIVERY OF BIOACTIVE MOLECULES USING IONTOPHORESIS,
which claims priority to U.S. Patent Application Ser. No.
62/094,663, filed Dec. 19, 2014, entitled INTRAOCULAR DELIVERY OF
BIOACTIVE MOLECULES USING IONTOPHORESIS, both of which are
incorporated herein by reference in their entireties.
BACKGROUND OF THE INVENTION
[0002] The present invention relates generally to the use of
bioactive molecules to ocular tissues and, more specifically, to
the delivery of lutein to the macula using iontophoresis.
[0003] Lutein (and zeaxanthin) are associated with reducing the
risk of developing AMD (Age-related Macular Degeneration) and
cataract extraction due to its antioxidant and photoprotective
effects, and its exclusive distribution in the eye macula.sup.1.
Age is one of the most important risk factors for AMD, typically
affecting individuals over 50 years old.sup.2-4. There are two
types of AMD, `dry AMD` and `wet AMD`. Dry AMD develops when
macular cells become damaged as a result of waste product
accumulation called "drusen". It is the most common and least
serious type of AMD. An estimated high number of those that present
dry AMD symptoms will develop wet AMD, which develops when abnormal
blood vessels from underneath the macula grow and lead to
irreversible cell damage.sup.2-4.
[0004] Lutein has been widely used through oral supplementation
with the rationale that systemic circulation can bring lutein to
the coroidal circulation for uptake into the macula, through
xanthophyll-binding proteins.sup.5. However, several reports
demonstrate that only a small percentage of lutein reaches the
macula.sup.6-8. Moreover, due to eye barrier limits, therapeutic
treatments in the posterior eye segment are difficult. Since the
eye is protected by the tear film, corneal, vitreous, blood-retinal
and blood-aqueous barriers, it is very difficult to deliver drugs
to the eye, particularly to the retina, in sufficient
concentrations and with minimal side-effects.sup.9,10. In-situ
applications have been used to overcome this problem; however, slow
delivery systems, such as implants, are very invasive and
expensive. Over the past few years, the results of many studies
have highlighted the risks of these treatments.sup.11,12.
[0005] Recently, intra-vitreous injections of lutein have been used
to stain specific preretinal membranes and other eye structures
during surgery.sup.13-16. This has been the first data on in-situ
delivery of lutein towards the macula, exploiting lutein's
intrinsic staining effect. Lutein's potential of delaying AMD
progression and putative neuroprotective action shown in different
trials has not yet been proven through in-situ application
following intraocular delivery. Intravitreous injection of lutein
for a prevention purpose may be too invasive as a strategy of
delivering lutein to the macula, with the disadvantage of poor
patient acceptance.
[0006] Ocular iontophoresis is a minimally invasive method used to
propel by electrical force high concentrations of target molecules
transsclerally or/and transcorneally. It uses a small electrical
current applied to an iontophoretic chamber containing the molecule
of interest and vehicle.sup.17. Several reports revealed that
lutein, which is found in high concentrations in the macula of the
human eye, has the potential of delaying AMD progression, in
addition to potential neuroprotective action.sup.18-20.
[0007] Here we report a novel way of delivering lutein to the
retina, so its presence in the parafovea macular region can be
enhanced significantly and thereby delay the progression of AMD and
protect retinal endothelial cells. Different iontophoresis delivery
systems for ophthalmic use have been created and have been used to
safely and effectively deliver medication to both the anterior and
posterior segments of the human eye.sup.21. With this technology,
it is possible to deliver significant amounts of bioactive
molecules, including macromolecules, across the cornea and sclera.
In the work reported here, a lutein emulsion has been diffusively
delivered to the macula by iontophoresis.sup.22-23. The idea was to
develop a minimally invasive method of propelling high
concentrations of charged lutein, transclerally or/and
transcorneally by iontophoresis. We have assessed the distribution
and concentration of lutein in the different ocular tissues using
two-photon microscopy, Raman spectroscopy and HPLC after scleral
and corneal iontophoretic application. The main advantage of this
approach is to use of a medical device that is safer and easier to
have patient compliance, avoiding the complications of frequent and
high dose injections or surgical implantations. This procedure can
be performed quickly in the doctor's office during a normal eye
care appointment with no need of a surgical environment.
SUMMARY OF THE INVENTION
[0008] Iontophoresis, a minimally invasive methodology that uses a
low electric current to enhance penetration of ionized compounds
into tissues, was found to be effective for the intraocular
delivery of lutein. Fourteen pigmented rabbits were treated by
application onto the cornea and sclera of an iontophoretic
reservoir filled with lutein emulsion with or without current (20.0
and 0.0 mA, respectively). After iontophoresis, the ocular tissues
from both eyes (test and control) were collected and lutein
delivery was assessed by visual comparison between treated eye and
untreated contralateral eye. The transcorneal and transscleral
iontophoresis application resulted in the delivery of lutein to the
rabbit cornea in all treated eyes (time 0 h). The application of
lutein also created an orange trace on the sclera limbus and a
slight orange coloration in the eye conjunctiva, demonstrating the
transport of the emulsion also to these tissues. In this work we
have shown for the first time that iontophoresis is an effective
technique for intraocular delivery of lutein.
[0009] In the present invention, lutein distribution in the eye
after iontophoresis procedure was assessed to confirm that high
quantities of lutein were delivered to the posterior retina by this
technique. Results indicate that iontophoresis is an effective
method of delivering a positively charged liposomal emulsion of
lutein into rabbits eyes. Furthermore, experiments were performed
using optimized formulations of lutein emulsion and an alternative
iontophoretic prototype to evaluate lutein distribution in
different eye tissues.
[0010] Trials were also performed with human cadaveric eyes to
which a low electric current was applied to evaluate lutein
delivery through the cornea and sclera. The cornea, sclera,
choroid, peripheral and central retina from treated and non-treated
eyes were collected and analyzed by two-photon microscopy in order
to visualize the distribution of lutein-containing liposomes.
[0011] The transscleral iontophoretic application resulted in the
delivery of the lutein mainly to the posterior retina region,
revealing the pathway of lutein after the iontophoresis occurs via
ciliary body/pars plana followed by passive diffusion until
reaching the posterior retina. The absence of lutein in the choroid
can be explained by the narrow size of tight junctions of the
retinal pigmented epithelium, which impair the passage of the
larger liposomal vesicles, thereby trapping lutein in the retina
inner layers.
[0012] With this work we demonstrated for the first time the in
situ delivery of lutein to the posterior eye segment through a
novel, minimally invasive method. The results demonstrate that
scleral iontophoresis of lutein is an effective strategy of
delivering lutein to the macula, which represents an alternative to
the current methods used to delay diseases in the posterior eye
segment, such as AMD.
[0013] Iontophoresis has the advantage of being a minimally
invasive method and, therefore, is safer than the alternative
methods of intraocular delivery of compounds, namely implants and
intra-ocular injections. Consequently, iontophoresis will have a
higher patient compliance since it avoids the complications of a
surgical implantation or frequent and high dose intravitreal
injections. Another advantage is this technique is less expensive
than those procedures and can be performed quickly in the doctor's
office during a normal eye care appointment with no need for a
surgery environment.
BRIEF DESCRIPTION OF THE FIGURES
[0014] The patent or application file contains at least one drawing
executed in color. Copies of this patent or patent application
publication with color drawing(s) will be provided by the Office
upon request and payment of the necessary fee.
[0015] FIG. 1 is a chart of Lipo+ absorption spectra (300 to
750nm), 1:50 dilution in 0.9% NaCl (blue) or distilled water (red);
the control spectrum (liposome solution without lutein) is
represented.
[0016] FIG. 2 is a chart of Lipo+ fluorescence spectra (480 to
650nm), 1:50 dilution in 0.9% NaCl (blue) or distilled water (red);
the control spectrum (liposome solution without lutein) is
represented.
[0017] FIG. 3 is a chart of the dynamic light scattering and
electrophoretic mobility to estimate particle size distribution and
charge of Lipo+ solution: a 1:50 dilution in distilled water (red)
was tested and also 1:50 liposome dilution in water (without
lutein) as control.
[0018] FIG. 4 is a schematic representation of lutein trajectory
after iontophoresis application; scleral application deposits
lutein to the back of the eye, whereas corneal application leaves
lutein sitting on top of the corneal epithelial cells (orange
spots); arrows indicate the entrance of lutein following
iontophoresis application.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
[0019] The terms "administration of" or "administering a" compound
should be understood to mean providing a compound of the invention
to the individual in need of treatment in a form that can be
introduced into that individual's body in a therapeutically useful
form and therapeutically effective amount, including, but not
limited to: oral dosage forms, such as tablets, capsules, syrups,
suspensions, and the like; injectable dosage forms, such as IV, IM,
or IP, and the like; transdermal dosage forms, including creams,
jellies, powders, or patches; buccal dosage forms; inhalation
powders, sprays, suspensions, and the like; and rectal
suppositories.
[0020] The term "effective amount" as used herein refers to the
amount necessary to elicit the desired biological response. As will
be appreciated by those of ordinary skill in this art, the
effective amount of a composite or bioactive agent may vary
depending on such factors as the desired biological endpoint, the
bioactive agent to be delivered, the composition of the
encapsulating matrix, the target tissue, etc.
[0021] As used herein, the term "extract" refers to a product
prepared by extraction. The extract may be in the form of a
solution in a solvent, or the extract may be a concentrate or
essence which is free of, or substantially free of solvent. The
term extract may be a single extract obtained from a particular
extraction step or series of extraction steps or the extract also
may be a combination of extracts obtained from separate extraction
steps. For example, extract "a" may be obtained by extracting
cranberry with alcohol in water, while extract "b" may be obtained
by super critical carbon dioxide extraction of cranberry. Extracts
a and b may then be combined to form extract "c". Such combined
extracts are thus also encompassed by the term "extract".
[0022] As used herein, the term "fraction" means the extract
comprising a specific group of chemical compounds characterized by
certain physical, chemical properties or physical or chemical
properties.
[0023] The term "preventing", when used in relation to a condition,
such as cancer, an infectious disease, or other medical disease or
condition, is well understood in the art, and includes
administration of a composition which reduces the frequency of, or
delays the onset of, symptoms of a medical condition in a subject
relative to a subject which does not receive the composition. Thus,
prevention of cancer includes, for example, reducing the number of
detectable cancerous growths in a population of patients receiving
a prophylactic treatment relative to an untreated control
population, and/or delaying the appearance of detectable cancerous
growths in a treated population versus an untreated control
population, e.g., by a statistically and/or clinically significant
amount. Prevention of an infection includes, for example, reducing
the number of diagnoses of the infection in a treated population
versus an untreated control population, and/or delaying the onset
of symptoms of the infection in a treated population versus an
untreated control population.
[0024] By "pharmaceutically acceptable" it is meant the carrier,
diluent or excipient must be compatible with the other ingredients
of the formulation and not deleterious to the recipient
thereof.
[0025] The term "synergistic" is well understood in the art and
refers to two or more components working together so that the total
effect is greater than the sum of the components.
[0026] The term "treating" is well understood in the art and refers
to curing as well as ameliorating at least one symptom of any
condition or disorder.
[0027] The term "prophylactic or therapeutic" treatment is well
understood in the art and includes administration to the host of
one or more of the subject compositions. If it is administered
prior to clinical manifestation of the unwanted condition (e.g.,
disease or other unwanted state of the host animal) then the
treatment is prophylactic, i.e., it protects the host against
developing the unwanted condition, whereas if it is administered
after manifestation of the unwanted condition, the treatment is
therapeutic (i.e., it is intended to diminish, ameliorate, or
stabilize the existing unwanted condition or side effects
thereof).
[0028] The compounds of this invention may be administered to
subjects (humans and animals, including companion animals, such as
dogs, cats and horses) in need of such treatment in dosages that
will provide optimal pharmaceutical efficacy. It will be
appreciated that the dose required for use in any particular
application will vary from patient to patient, not only with the
particular compound or composition selected, but also with the
route of administration, the nature of the condition being treated,
the age and condition of the patient, concurrent medication or
special diets then being followed by the patient, and other factors
which those skilled in the art will recognize, with the appropriate
dosage ultimately being at the discretion of the attendant
physician.
EXAMPLE 1
Intra-ocular Delivery of Lutein in Rabbit Eyes
Materials and Methods
[0029] Formulation work. Among the different delivery systems
currently used to improve the stability of compounds, liposomes
have advantages due to their biocompatibility, sustained release
potential, and the ability to carry both hydrophobic and
hydrophilic compounds.sup.16. In this work, crystalline lutein
(Kemin Foods, FloraGLO.RTM. Crystalline Lutein lot. 1401103302) was
encapsulated in liposomes using phospholipids 90H (Lipoid GmbH, lot
529400-2120046-12-112, CAS 308068-11-3) and octadecylamine
(Sigma-Aldrich lot BCBK6340V, CAS 124-30-1). Lipid film was
prepared using 90H phospholipids, octadecylamine and lutein
dissolved in CHCl.sub.3/MeOH (2:1) (Sigma-Aldrich, lot SHBC4982V,
CAS 67-66-3/Sigma-Aldrich, lot SZBC237BV, CAS 67-56-1). Solvents
were removed under vacuum by rotary evaporation; the solution was
dried under vacuum at 40.degree. C. by a Heidolph rotavapor, the
speed of the rotavapor was modulated in order to reduce bubble
formation and splashing that could cause loss of product and a dry
thin film was obtained after 1-2 hours. To remove any trace of
solvents, the thin film was left under vacuum for at least 16 hours
at room temperature. Lipid film hydration was performed by adding
distilled water (Water Ultrapure--MilliQ-by AquaMax--conductivity
0.054 uS/cm) at 40-45.degree. C. to the lipid film to hydrate
lipids and form large liposome vesicles. The homogenization of the
large liposome vesicles was achieved using Ika Works ULTRA-TURRAX T
25 Digital Homogenizer (Staufen, Germany), and reduction of
liposome vesicles to a nano size range has been performed by
extrusion using large-scale Microfluidizer.RTM. high fluid
processor M-110EH at 50-60.degree. C. and 1200 bar. This process
was repeated 5 times. Sterilization of the emulsion was performed
at 121.degree. C. for 20 minutes at 1 atm. Table 1 shows liposome
emulsion composition. Size distribution, zeta potential, osmolality
and pH of the final product were analyzed after sterilization and
are summarized in Table 2.
TABLE-US-00001 TABLE 1 Lutein liposome emulsion composition.
Composition % w/w 90H phospholipids 1.000 Octadecylamine 0.005
Lutein crystals 0.050 Distilled water to 100 g
TABLE-US-00002 TABLE 2 Liposome characteristics after
sterilization. Osmolality Mean diameter Zeta potential pH (mOsM/kg)
(nm) (mV) 6.84 15 194 +36.93
[0030] Ocular iontophoresis device. The iontophoresis device
consisted of two disposable components: an ocular applicator and a
return electrode. These two components were connected to a reusable
generator. The ocular applicator was composed by a polycarbonate
reservoir (diameter 9 mm, height 4.5 mm, volume 0.5 ml) and a
stainless steel electrode (AISI 304) connected with a lead to the
generator (anode--positive electrode). The return electrode was a
25G intradermic needle, inserted in the neck (front side) and
connected with a crocodile clip and lead to the generator
(cathode). The generator (EYEGATE CCI Generator 6121-EYE, Eyegate
Pharma, Paris France) was a constant current type, setting range
0.25 mA-2.5 mA (10 increments of 0.25 mA) for the current and 0.5
min-5 min for the time (10 increments of 0.5 min). The resulting
voltage applied was measured during the study with a
multimeter.
[0031] Animals. Fourteen pigmented rabbits strain HY79b (Breeder:
"HYPHARM"--FR-49450 ROUSSAY) were used in this study. All animals
were identified individually using an ear tag and using a marker in
the ears following the inclusion examination. Animals were held in
observation for 3 days following their arrival, and were daily
observed for signs of illness with particular attention to the
eyes. Animals were individually housed in standard cages, under
identical environmental conditions. The temperature was held at
15-21.degree. C. and the relative humidity at 55.+-.10%. Rooms were
continuously ventilated (.gtoreq.15 air volumes per hour).
Temperature and relative humidity were continuously controlled and
recorded. Animals were routinely exposed (in-cage) to a 10-200
l.times. light in a 12-hour light (from 7:00 a.m. to 7:00 p.m.) and
12-hour darkness controlled cycle. Throughout the study, animals
had free access to food and water. They were fed a standard dry
pellet diet (150 g/day), LASQCdiet.RTM. Rab-14H (LASVENDI GMBH,
Soest Germany). Tap water, regularly analysed, was available ad
libitum from plastic bottles. All standard operating procedures and
protocols described in this study plan have been reviewed by a
certified Ethical Committee. All animals were treated according to
the Directive 2010/63/UE European Convention for the Protection of
Vertebrate Animals used for Experimental.sup.17 and Other
Scientific Purposes and to the Association for Research in Vision
and Ophthalmology (ARVO) Statement for the Use of Animals in
Ophthalmic and Vision Research.sup.18.
[0032] Experimental procedure. Fourteen pigmented rabbits from
HY79b strain were randomly divided into two groups: control
(passive application: without electric current; animals #9-14) and
test group (iontophorectic application: with electric current;
animals #1-8). These two groups were subdivided in two time-points
(0 and 2 hours). Table 3 summarizes the study design.
TABLE-US-00003 TABLE 3 Study design. Group No. Drug Administration
Time-points Animals id# 1 Lutein Iontophoretic delivery 0 h 1, 2,
3, 4 2 emulsion (charge = 20.0 mA) 2 h 5, 6, 7, 8 3 Iontophoretic
delivery 0 h 9, 10, 11 4 (charge = 0.0 mA) 2 h 12, 13, 14
[0033] Lutein emulsion was administered by iontophoresis to
anesthetized animals (intra muscular injection of a mix
xylazine/ketamine), aided with a blepharostat and under local
anesthesia (one drop of Cebesine.RTM.: 0.4% oxybuprocaine, Thea,
lot F6757) about 10 min before application). Animals were treated
by application onto the cornea and sclera of a 9-mm iontophoretic
applicator filled with lutein for 10 minutes on right eye. A charge
of 0.0 mA or 20.0 mA was applied on each eye, depending on the
group (see Table 3). The iontophoretic applicator was impregnated
with 0.5 mL of lutein liposome emulsion just before dosing; the
electrode of the device was covered with lutein emulsion. All
administrations were followed by balanced salt solution (BSS)
washing.
[0034] Immediately after the iontophoretic application of the right
eye or 2 hours post-application (see Table 3), animals were
euthanized by intravenous administration of overdosed
pentobarbital, which is among the recommended methods by the
European Authorities.sup.17. Cornea (C), aqueous humor (AH),
ciliary-body (CB), retina (R), vitreous (V) and sclera (SC) from
both eyes were sampled and weighed. A visual evaluation of the
coloration of the samples was performed before storing them at
-80.degree. C. for future HPLC (high-performance liquid
chromatography) analysis.
Results
[0035] Ocular iontophoretic delivery of lutein emulsion in
pigmented rabbits. In order to evaluate the capacity of lutein to
be delivered by iontophoresis, we produced liposomes carrying
lutein (positively charged) and applied this emulsion for 10 min
with 2.0 mA into the cornea/sclera of pigmented rabbits. The
efficacy of delivery by iontophoresis was evaluated by visual
assessment of the collected tissues. Table 4 summarizes the results
after the application of lutein emulsion, with and without
current.
TABLE-US-00004 TABLE 4 Coloration after iontophoretic application.
Tissue Ocular tissue coloration (upon sampling) Rabbit collection
Untreated eye Treated eye ID# Iontophoresis time-point (left)
(right) 1 2.0 mA charge 0 h No coloration Cornea: slight circular
orange for 10 min trace 2 No coloration Cornea: circular orange
trace. SC: orange trace on the limbus. CJ: slight orange coloration
3 No coloration Cornea: circular orange trace. SC: orange trace on
the limbus. CJ: slight orange coloration 4 No coloration Cornea:
circular orange trace 5 2 h No coloration Cornea: circular orange
trace 6 No coloration No coloration 7 No coloration No coloration 8
No coloration Cornea: circular orange trace 9 10 min 0 h No
coloration No coloration 10 application No coloration No coloration
11 without charge No coloration No coloration 12 2 h No coloration
No coloration 13 No coloration No coloration 14 No coloration No
coloration Note: C = Cornea; SC = Sclera; CJ = Conjunctiva
[0036] Subsequently to the iontophoresis application, all the eyes
treated with 20.0 mA of current (time 0 h) revealed a circular
orange color in the cornea revealing the present of lutein emulsion
in the tissues. The application of lutein also originated in two
eyes (#2 and #3) an orange trace on the sclera limbus and a slight
orange coloration in the eye conjunctiva. After 2 h of treatment
only half of the treated eyes showed this coloration in the cornea
(#5 and #8), this event may indicate that subsequently to the
application, the emulsion diffuses into the eye. No delivery into
the different ocular tissues was observed without current.
Discussion
[0037] Approximately 10% of people over 65 years around the world
suffer from AMD disease.degree. . Different trials have indicated
lutein is a potential AMD progression delayer and also a potential
neuroprotective molecule.sup.13, 20-22. Moreover, lutein is a
natural component of the eye, with intrinsic macular tropism, being
specifically deposited in the para-foveal area where it is
congenital.sup.1. These features can be an advantage towards the
current products used to control AMD. The available treatments for
this pathology involve intraocular injections that have side
effects, are troublesome to the patient and expensive, so the
development of a more safe and effective treatment is crucial. Over
the past few years, results of many studies have highlighted the
risks of intravitreal injections. The need for frequent
administration of drugs through intravitreal injections can lead to
retinal detachment, endophthalmitis and increased intraocular
pressure. Both noninfectious and infectious inflammation has been
reported as complications of intravitreal injections. With the
increasing rates of intravitreal injections since their approval
for use, the incidence of infectious endophthalmitis has been
extensively studied.sup.23,24. In this work we tested, for the
first time a minimally invasive technology to deliver lutein
in-situ. Iontophoresis has the advantage of being a minimally
invasive method and therefore is safer and easier to improve
patient compliance, since it avoids the complications of a surgical
implantation or frequent and high dose of intravitreal
injections.sup.12. In fact different pre-clinical and clinical
studies reported the safety of repeated ocular iontophoresis
applications.sup.14, 25, 26. Another advantage is this method is
less expensive and can be performed quickly in the doctor's office
during a normal eye care appointment with no need for a surgery
environment. Different studies established the use of iontophoresis
for the treatment of human eye diseases, for instance in management
of active corneal graft rejection.sup.27, treatment of dry eye
disease.sup.14, 28, noninfectious anterior uveitis.sup.15 and
keratoconus disease.sup.29.
[0038] In this investigation we have used iontophoresis that
involves the application of a weak direct current during 10 minutes
that drives charged molecules across the eye tissues. The
iontophoretic application resulted in the penetration of the
emulsion of liposomes carrying lutein (ionized drug) through the
corneal segment of the eye.
[0039] This study is an effective proof-of-concept that clearly
shows an intraocular delivery of lutein emulsion through
iontophoresis technique.
EXAMPLE 2
Intra-ocular Delivery of Lutein in Cadaveric Eyes
Materials and Methods
[0040] Formulation work. It has been demonstrated that positive
particles are better candidates for iontophoretic application as
drug carrier than the negatively charged particles due to higher
penetration into ocular tissues.sup.38. Furthermore, the electrical
field forces the positive charged molecules to move into eye
membranes (negatively charged).sup.39. In this work we took
advantage of the fact that the membranes present in the human eye,
at physiological pH, are negatively charged and for developing a
positively charged emulsion carrying lutein to be delivered through
iontophoresis application. Due to the fact that lutein is a
molecule with a large molecular weight, lipophilic and insoluble in
water, the delivery of this carotenoid trough iontophoresis without
modifications is nearly impossible.sup.1. In order to overcome
that, a formulation with positively charged liposome vesicles that
behave as carriers of lutein molecules was prepared (Lipo+).The
lipid film was prepared using phospholipon 90H (Lipoid GmbH, lot
529400-2120046-12-112, CAS 308068-11-3), octadecylamine
(Sigma-Aldrich lot BCBK6340V, CAS 124-30-1) crystalline lutein
(Kemin Health, FloraGLO.RTM. Crystalline Lutein lot. 1401103302).
For preparation of 4-5 L, the compounds were dissolved in 500-800
mL of CHCl.sub.3/MeOH (1:1 v/v) (Sigma-Aldrich, lot SHBC4982V, CAS
67-66-3/Sigma-Aldrich, lot SZBC237BV, CAS 67-56-1) by heating at
30-35.degree. C. Please see formulation composition in Table 5.
Solvents were removed under vacuum by rotary evaporation; the
solution was dried under vacuum at 40.degree. C. by a Heidolph
rotavapor, and a dry thin film was obtained after 1-2 hours. The
thin film was left under vacuum for at least 16 hours at room
temperature to ensure the complete removal of any trace of
solvents. The content of organic solvents was analyzed by gas
chromatography (GC) and was assured to be less than 25 ppm. Lipid
film hydration was performed by adding distilled water (Water
Ultrapure--MilliQ-by AquaMax--conductivity 0.054 uS/cm) at
65.degree. C. to the lipid film to form large liposome vesicles.
Homogenization of these large liposomes vesicles was achieved using
Ika Works ULTRA-TURRAX T 25 Digital homogenizer (Staufen, Germany)
at 2000-4000 rpm and reduction of liposome vesicles to nano size
range has been performed by extrusion using large-scale
Microfluidizer.RTM. high fluid processor M-110EH at 50-60.degree.
C. and 1200 bar. This process was repeated 5 times. Sterilization
of the emulsion was performed at 121.degree. C. for 20 minutes at 1
atm. After the sterilization process, the characteristics of the
liposomal formulation were recorded: pH (using a Mettler Toledo S20
instrument), osmolality (using Osmomat 3000), particle size and
zeta potential (using dynamic light scattering (DLS), also known as
photon correlation spectroscopy technique--Nicomp 380 DLS.
TABLE-US-00005 TABLE 5 Lutein liposome emulsion composition.
Composition % w/w 90H phospholipids 2.000 Octadecylamine 0.007
Lutein crystals 0.100 Distilled water to 100 g
[0041] Spectrophotometric evaluation of the formulation.
Spectrophotometry was used to measure the absorbance and
fluorescence properties of the Lipo+ solution (1:50 dilution in
water or 0.9% NaCl). A solution including only liposomes (without
lutein) was used as control. The absorbance spectra were traced
between 300 and 750 nm for each sample and the fluorescence spectra
between 480 and 650 nm, with excitation at 370 nm (chosen from the
absorbance spectra results).
[0042] Particle size and zeta-potential. Dynamic light scattering
was used to evaluate the distribution of sizes of the components in
the Lipo+ solution. Electrophoresis was performed to evaluate the
zeta potential of the solution.
[0043] Ocular iontophoretic device. The principle of ocular
iontophoresis is applying an electric field to an electrolytic
substance containing at least one product, in order to transport
the product into the body or the organ to be treated, via the
biological membranes of the eye.sup.12.
[0044] A typical iontophoretic setting is made of two components:
ocular applicator and a return electrode both connected to a
generator. In this experiment, the ocular applicator comprised 2
electrodes to address independently corneal and scleral tissues.
The ocular applicator (OPIA Technologies SAS, Paris, France) is
made of polyurethane resin and comprises 2 reservoirs: central
circular reservoir (diameter 8 mm, height 4.5 mm, volume 1 ml) and
a stainless steel electrode, applied on the cornea surrounded by an
annular reservoir (inner diameter 12.5 mm, outer diameter 18 mm
height 4.5 mm, volume 1 ml) and a stainless steel electrode,
applied on the sclera (pars plana region around the limbus). Each
stainless steel electrode connected with a lead to a different
constant current generator (anode--positive electrode). The return
electrodes were assigned to each generator and respectively
attached to the optic nerve (for the corneal electrode) and the
equator region of the sclera (for scleral electrode), closing each
electrical circuit independently. The generators (IONO-25, Iacer
Srl, Italy) were a constant current type, setting range 0.25 mA-2.5
mA (5 increments of 0.5 mA) for the current and time adjusted
automatically to deliver a total dose of 20 mA.min. The resulting
voltage applied was measured during the study for each circuit with
2 multimeters.
[0045] Cadaveric eyes. Six human cadaveric eye globes, from
different healthy donors, were obtained from the Veneto Eye Bank
Foundation (Venezia Zelarino, Italy). The human eyes were used in
compliance with the guidelines of the Declaration of Helsinki for
research involving the use of human tissue and were explanted
between 3 and 16 hours after death and immediately preserved at
4.degree. C. in corneal storage medium enriched with 6% dextran.
The mean donor age was 63.6.+-.5.9 years. The mean endothelial cell
density was 2125.+-.389 cells/mm.sup.2. Each eye globe, submerged
in dextran enriched solution, was shipped to the laboratory within
5 days. Four eye globes underwent corneo-scleral iontophoresis to
deliver 0.1% lutein ophthalmic solution into the retinal tissue.
Two eye globes were used as control: iontophoresis was performed
without presence of the formulation.
[0046] Preparation of the eyes. Each eye globe was gently mounted
into a specially designed holder, facing upward. The scleral and
corneal passive electrodes were applied in the optic nerve and
sclera, respectively. The eye was connected to a column manometer
by a tube, filled with 0.9% sodium chloride solution, in order to
maintain the pressure inside the eye at 15 mmHg during the
experiment. The eye globe was first subjected to three cycles of
pre-conditioning between 15 and 42 mmHg in order to stabilize the
ocular tissues and mechanics during experiment. This
preconditioning ensured to attain a unique reference state at the
beginning of each experiment and to restore the corneal and scleral
thickness to physiological levels. After pre-conditioning, the
central corneal thickness (CCT) was measured, using an ultrasound
corneal pachymeter (Pachmate, DGH, Exton, USA). In these samples,
the mean CCT was 558.+-.19 pm.
[0047] Impregnation with the solution. The active electrode
(cathode), in a plastic bath, was applied to the corneal and
scleral surface. The plastic tube was filled with foam, which was
soaked with Lipo+ for 20 minutes. After this pre-soaking treatment,
the tube was gently applied to the anterior surface of the eye
globe and again filled with 2 mL of Lipo+ solution. The current
density was set at 2.5 mA and delivered for 5 minutes for both
generators connected to the cornea and sclera. After corneo-scleral
iontophoresis, the eye globe was maintained, facing upward, in the
eye holder with the pressure inside the eye at 15 mmHg for 80
minutes. This period allowed the lutein, which reached the retina
by trans-scleral iontophoresis, to diffuse passively, through the
retinal tissue, towards the macula, specially the para-foveal
region. Two of the 6 eyes used in this study were used as control,
thus no impregnation with the formulation was performed.
[0048] Tissue evaluation. After 80 minutes, the retinal tissue was
isolated without inducing gross damage that could compromise their
use for high-resolution two-photon imaging. Dissection of retinal,
choroidal, corneal and scleral tissues was done using a
standardized protocol.sup.47. Two-photon microscopy was used to
evaluate penetration of lutein in the macular region of the retina.
Before starting image acquisition on ocular tissues, several stacks
on Lipo+ solution (0.005%, 0.002% and 0.001% dilutions in 0.9%
sodium chloride) were acquired in order to understand the best
filter to apply and enhance the two-photon fluorescence (TPF)
signal emitted by lutein. The filter 550/80 nm (Semrock) was the
most appropriate for the study of lutein (based in
spectrophotometric studies) however, the filter 525/20 nm (Semrock)
was found to give good results in terms of Signal-to-noise ratio
(SNR). Therefore, the excitation used for ocular tissues evaluation
was 835 nm and TPF light emitted by ocular tissue components was
collected in backward direction by a non-descanned detector (NDDI)
for reflected light reflection.
[0049] Resonance Raman Spectroscopy: Resonant Raman scattering was
used for evaluating the efficacy of iontophoresis delivery of
lutein to the human retina in cadaveric eyes. A single-mode laser
source (50 mW power), centered at 473.5 nm wavelength, was used as
excitation source to perform resonance Raman spectroscopy
measurement. The laser beam was focused on the ocular tissues by a
combination of lenses and a microscope objective (NA=0.25), so that
the irradiated retina area was 1 mm in diameter; the laser power
was reduced to 1 mW at the retinal plane using a neutral density
filter. The Raman scattered light was collected by a
photomultiplier tube (PMT), with spectral resolution of 10
cm.sup.-1 and with an average of 80 dark counts rate. Raman signal
intensity was recorded as photon counts per second (cps).
Measurements were performed on three retinal regions: the inner
sclera at the site of iontophoretic delivery (i.e., the perilimbal
sclera facing towards the ciliary body); the retinal mid-periphery,
which included the region of the retina surrounding the vascular
arcades and the optic nerve head; and the macula. Measurements were
performed in four areas across each region in order to collect
enough data to correctly estimate data in the study and control
eyes. Before the experiment, in order to find a correlation between
the Raman readings and the actual lutein content of the ocular
tissues, calibration experiments using thin quartz cuvettes filled
with different concentration of lutein were performed.
Results
[0050] Lipo+ spectral characteristics. Absorbance and fluorescence
spectra of Lipo+ solution were initially addressed in this study in
order to determine the two-photon excitation wavelength. The
absorption spectra were traced between 300 and 750 nm and are
represented in FIG. 1. The Lipo+ solution showed an absorption peak
at 370 nm and this was used as excitation wavelength to trace Lipo+
fluorescence spectra between 480 and 650 nm (FIG. 2). Lipo+ showed
two fluorescent band peaks: 500-530 nm and 540-570 nm. Based on
these results, the filter chosen for the two-photon experiments was
the 550/88.
[0051] Lipo+ physical characteristics. Particle size and
zeta-potential were also determined before iontophoresis testing,
in order to confirm Lipo+ positive charge and size. These
determinations were performed through dynamic light scattering and
electrophoresis, respectively, for a 1:50 Lipo+ dilution in
distilled water, and were also compared to the lutein-free liposome
solution (as control). According to FIG. 3, Lipo+ aggregates peak
at 3.5 .mu.m (in average) and a smaller peak is also seen at 300 nm
(in average), indicative of the individual liposomes. Also, the
zeta potential determination showed a +5 mV charge for the Lipo+
solution.
[0052] Lutein distribution in cadaveric eyes after iontophoretic
application. Although the filter chosen for the two-photon
experiments was the 550/88 (based on previous fluorescence
experiments), initial analysis of the lutein liposomal formulation
revealed that the 525/20 filter gave better results in terms of
SNR. In this initial calibration (with 0.005, 0.002 and 0.001%
Lipo+ dilutions in 0.9% % NaCl), liposomes were observed as
spherical vesicles and the microscope was calibrated correctly
(data not shown). This is a very important control because the
retinal pigment cells are full of melanin, a pigment that excites
at the same wavelength as lutein. Moreover, with this control we
are able to distinguish between the lutein liposomes and the
pigment.
[0053] In order to assess the distribution of the liposomes
carrying lutein in human eye after iontophoretic application, five
cadaveric eyes were exposed to a current of 2.5 mA for 5 min into
the cornea/sclera, allowed to rest for 80 min (controlled
intraocular pressure at 15 mmHg) and the different structures of
the eye were collected: cornea, sclera, choroid, peripheral and
central retina. The distribution of the liposomes was evaluated by
two-photon microscopy (excitation at 835 nm). A sixth cadaveric eye
was used as control: the eye was never in contact with the
liposomal formulation. In this, no liposomes were detected when the
835 nm laser was on, indicating that the signal is specific to
exogenous lutein (data not shown).
[0054] Analysis of the different eye tissues collected showed that
after combined corneo-scleral iontophoresis, lutein was abundant in
the retina, while no lutein-enriched liposomes were found in the
choroidal tissues for all tested eyes with the formulation.
[0055] Also, from the retinal investigation, Lipo+ solution was not
able to cross the wall of retinal vessels, since liposomes were
only found in the tissue surrounding the vessels.
[0056] For the anterior segment determinations (sclera and cornea),
no lutein-enriched liposomes were found, neither in the corneal
stroma nor in the sclera tissue, but were found in corneal
epithelial cells
[0057] In the retina it was also possible to observe more lutein in
the outer part close to the photoreceptors than in the ganglion
cells, the inner part of the retina.
[0058] Since the choroid analysis revealed no liposomes were
present in this region after the current application, these results
indicate that after transscleral application of lutein by
iontophoresis via ciliary body/pars plana, lutein liposomes diffuse
passively through the eye membranes until reaching the posterior
retina near the fovea. FIG. 4 shows a schematic representation of
the lutein pathway within the eye. Analysis of corneal tissue
following corneal iontophoresis application, revealed the liposomes
were sitting on top of the epithelial cells of this tissue.
[0059] Resonance Raman spectroscopy analysis of different eye
tissues was also performed. Raman signals were superimposed on a
fluorescence background likely originating from intrinsic
carotenoid fluorescein and lipofuscin fluorescence. To obtain an
accurate reading of the Raman peak heights, free of background
signals, we subtracted the influence of potentially overlapping
noise spikes in the spectrum by polynomial fitting (up to 5th
order) of the measured Raman line shapes for each measured
spectrum. The final peak height of the C.dbd.C double bond signal
at 1530 cm-1 was chosen as a signature of the presence of
lutein.
[0060] In the inner sclera, the Raman peak at 1530 cm-1 measured in
a treated eye was 7 times greater than control eye, providing the
evidence of efficacy of iontophoresis in delivering lutein to the
eye through the intact sclera. In the retinal mid-periphery, the
Raman peak at 1530 cm-1 measured in a treated eye was 1.7 times
greater than control eye, which indicated that a large amount of
lutein reached the posterior pole of the retina at the end of
iontophoresis treatment. In the macula, the Raman peak at 1530 cm-1
measured in a treated eye was 1.3 times greater than in controls,
demonstrating that iontophoresis was effective in delivering lutein
in the macula.
Discussion
[0061] Age-related macular degeneration (AMD) is the leading cause
of irreversible blindness in people over 50 years in the developed
world.sup.40, 41. More than 8 million Americans have AMD, and the
overall prevalence of the disease is projected to increase by more
than 50% by the year 2020.sup.37. Several epidemiological studies
highlighted that lutein supplementation lead to an increase in the
macular pigment optical density (MPOD) levels in early-stage AMD
patients, being associated with protection from macular
disease.sup.42, 21. In fact, lutein is naturally concentrated in
the retina, where together with zeaxanthin forms the macular
pigment. Acting as a blue light filter, lutein can protect the
underlying photoreceptors in the center of the macula from
photochemical damage.sup.43. The anti-oxidant properties of lutein
may also protect the macula from oxidative stress.sup.44.
[0062] The available solutions to slow AMD progression are based on
intraocular injections or surgeries, encompassing evidenced side
effects and possible complications such as retinal detachment,
increased intraocular pressure and also noninfectious and
infectious inflammation.sup.23,33. In this work, we used a
minimally invasive in situ delivery of lutein to the posterior
segment of the human eye. Iontophoresis has the advantage to be
safer and easier method to have patient compliance and propelling
high concentrations of a product of interest through the different
eye layers until it reaches the retina. Different reports have
established the safety of repeated treatments using ocular
iontophoresis for the treatment of different diseases such as dry
eye, noninfectious uveitis and keratoconus14,15,25,26,28,29.
[0063] Herein, using cadaveric eyes as pre-clinical model we
applied a weak electric current to propel lutein into the eye,
without side effects. We observed that lutein liposomes are mainly
deposited in the peripheral and central retina near the fovea, but
were absent from the choroidal regions. With this observation it is
possible to extrapolate the pathway of lutein after a transscleral
application is via ciliary body/pars plana, followed by passive
diffusion through the ocular membranes until reaching the posterior
retina region (FIG. 4). We proved for the first time that
transscleral iontophoresis is an effective way of bringing lutein
to the retina of the human eye providing a new way of fortifying
the macular pigment. Upon deposition in the posterior region, it is
postulated that lutein is able to reach the outer part of the
retina where the photoreceptors are present, by passive
diffusion/protein gradient. It can be argued the reason why lutein
was not observed in the choroid is due to the neural retinal
barrier which mesh size is 80-90 nm.sup.45 (liposomes are 341 nm in
size and can sometime form clusters of 2-3 .mu.m, suggesting that
lutein liposomes stay trapped in the retina (FIG. 4). Importantly,
resonance Raman spectroscopy analysis revealed that lutein
concentration is increased in the macula after iontophoresis. This
observation clearly demonstrates that transscleral iontophoresis is
an efficacious method of lutein delivery to the macula and is a
valid alternative to the current methods for preventing the onset
of AMD, prevent its progression and/or treat established
disease.
[0064] After corneal iontophoresis application no liposomes were
present in the corneal stroma. This fact can be explained since
lutein is hydrophobic and the stroma is 70% composed of water, so
very hydrophilic.sup.46, which makes impossible for lutein to
penetrate in this tissue.
[0065] The foregoing description and drawings comprise illustrative
embodiments of the present inventions. The foregoing embodiments
and the methods described herein may vary based on the ability,
experience, and preference of those skilled in the art. Merely
listing the steps of the method in a certain order does not
constitute any limitation on the order of the steps of the method.
The foregoing description and drawings merely explain and
illustrate the invention, and the invention is not limited thereto,
except insofar as the claims are so limited. Those skilled in the
art that have the disclosure before them will be able to make
modifications and variations therein without departing from the
scope of the invention.
REFERENCES
[0066] 1. Kijlstra A., Tian Y., Kelly E. R., Berendschot T. T.
2012. Lutein: more than just a filter for blue light. Prog Retin
Eye Res. 31:303-315. [0067] 2. Yemelyanov A. Y., Katz N. B.,
Bernstein P. S. 2001. Ligand-binding characterization of
xanthophyll carotenoids to solubilized membrane proteins derived
from human retina. Exp Eye Res. 72:381-392. [0068] 3. Bone R. A.,
Landrum J. T., Guerra L. H., Ruiz C. A. 2003. Lutein and zeaxanthin
dietary supplements raise macular pigment density and serum
concentrations of these carotenoids in humans. J Nutr. 133:992-998.
[0069] 4. Landrum J. T., Bone R. A., Joa H., Kilburn M. D., Moore
L. L., Sprague K. E. 1997. A one year study of the macular pigment:
the effect of 140 days of a lutein supplement. Exp Eye Res.
65:57-62. [0070] 5. Ma L., Lin X. M. 2010. Effects of lutein and
zeaxanthin on aspects of eye health. J Sci Food Agric. 90:2-12.
[0071] 6. Barar J., Javadzadeh A. R., Omidi Y. 2008. Ocular novel
drug delivery: impacts of membranes and barriers. Expert Opin Drug
Deliv. 5:567-581. [0072] 7. de la Fuente M., Ravina M., Paolicelli
P., Sanchez A., Seijo B., Alonso M. J. 2010. Chitosan-based
nanostructures: a delivery platform for ocular therapeutics. Adv
Drug Deliv Rev. 62:100-117. [0073] 8. Sousa-Martins D., Maia M.,
Moraes M., Lima-Filho A. A., Rodrigues E. B., Chen J., Farah M. E.,
Santos L. B., Belfort R., Jr. 2012. Use of lutein and zeaxanthin
alone or combined with Brilliant Blue to identify intraocular
structures intraoperatively. Retina. 32:1328-1336. [0074] 9.
Rodrigues E. B., Costa E. F., Penha F. M., Melo G. B., Bottos J.,
Dib E., Furlani B., Lima V. C., Maia M., Meyer C. H., Hofling-Lima
A. L., Farah M. E. 2009. The use of vital dyes in ocular surgery.
Surv Ophthalmol. 54:576-617. [0075] 10. Maia M., Furlani B. A.,
Souza-Lima A. A., Martins D. S., Navarro R. M., Belfort R., Jr.
2014. Lutein: a new dye for chromovitrectomy. Retina. 34:262-272.
[0076] 11. Badaro E., Furlani B., Prazeres J., Maia M., Lima A. A.,
Souza-Martins D., Muccioli C., Lucatto L. F., Belfort R., Jr. 2014.
Soluble lutein in combination with brilliant blue as a new dye for
chromovitrectomy. Graefes Arch Clin Exp Ophthalmol. 252:1071-1078.
[0077] 12. Eljarrat-Binstock E., Domb A. J. 2006. Iontophoresis: a
non-invasive ocular drug delivery. J Control Release. 110:479-489.
[0078] 13. Izumi-Nagai K., Nagai N., Ohgami K., Satofuka S., Ozawa
Y., Tsubota K., Umezawa K., Ohno S., Oike Y., Ishida S. 2007.
Macular pigment lutein is antiinflammatory in preventing choroidal
neovascularization. Arterioscler Thromb Vasc Biol. 27:2555-2562.
[0079] 14. Patane M. A., Cohen A., From S., Torkildsen G., Welch
D., Ousler G. W., 3rd. 2011. Ocular iontophoresis of EGP-437
(dexamethasone phosphate) in dry eye patients: results of a
randomized clinical trial. Clin Ophthalmol. 5:633-643. [0080] 15.
Cohen A. E., Assang C., Patane M. A., From S., Korenfeld M., Avion
Study I. 2012. Evaluation of dexamethasone phosphate delivered by
ocular iontophoresis for treating noninfectious anterior uveitis.
Ophthalmology. 119:66-73. [0081] 16. Tan C., Xia S., Xue J., Xie
J., Feng B., Zhang X. 2013. Liposomes as vehicles for lutein:
preparation, stability, liposomal membrane dynamics, and structure.
J Agric Food Chem. 61:8175-8184. [0082] 17. French Decree n.degree.
2013-118. 2013 European directive 2010/63/UE. J. Offic. Rep. Fr
Text 24 out of 130. [0083] 18. ASSOCIATION FOR RESEARCH IN VISION
AND OPHTHALMOLOGY (ARVO). 1995. Statement for the Use of Animals in
Ophthalmic and Vision Research. [0084] 19. Ratnapriya R., Chew E.
Y. 2013. Age-related macular degeneration-clinical review and
genetics update. Clin Genet. 84:160-166. [0085] 20. Age-Related Eye
Disease Study 2 Research G. 2013. Lutein+zeaxanthin and omega-3
fatty acids for age-related macular degeneration: the Age-Related
Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA.
309:2005-2015. [0086] 21. Richer S., Stiles W., Statkute L., Pulido
J., Frankowski J., Rudy D., Pei K., Tsipursky M., Nyland J. 2004.
Double-masked, placebo-controlled, randomized trial of lutein and
antioxidant supplementation in the intervention of atrophic
age-related macular degeneration: the Veterans LAST study (Lutein
Antioxidant Supplementation Trial). Optometry. 75:216-230. [0087]
22. Zhao L., Sweet B. V. 2008. Lutein and zeaxanthin for macular
degeneration. Am J Health Syst Pharm. 65:1232-1238. [0088] 23.
Simunovic M. P., Rush R. B., Hunyor A. P., Chang A. A. 2012.
Endophthalmitis following intravitreal injection versus
endophthalmitis following cataract surgery: clinical features,
causative organisms and post-treatment outcomes. Br J Ophthalmol.
96:862-866. [0089] 24. Irigoyen C., Ziahosseini K., Morphis G.,
Stappler T., Heimann H. 2012. Endophthalmitis following
intravitreal injections. Graefes Arch Clin Exp Ophthalmol.
250:499-505. [0090] 25. Patane M. A., Schubert W., Sanford T., Gee
R., Burgos M., Isom W. P., Ruiz-Perez B. 2013. Evaluation of ocular
and general safety following repeated dosing of dexamethasone
phosphate delivered by transscleral iontophoresis in rabbits. J
Ocul Pharmacol Ther. 29:760-769. [0091] 26. Patane M. A., Cohen A.,
Assang C., From S. 2010. Randomized, double-masked study of EGP-437
in subjects with non-infectious anterior segment uveitis. Poster
presented at: American Academy of Ophthalmology annual meeting.
[0092] 27. Halhal M., Renard G., Courtois Y., BenEzra D.,
Behar-Cohen F. 2004. Iontophoresis: from the lab to the bed side.
Exp Eye Res. 78:751-757. [0093] 28. Horwath-Winter J., Schmut O.,
Haller-Schober E. M., Gruber A., Rieger G. 2005. Iodide
iontophoresis as a treatment for dry eye syndrome. Br J Ophthalmol.
89:40-44. [0094] 29. Arboleda A., Kowalczuk L., Savoldelli M.,
Klein C., Ladraa S., Naud M. C., Aguilar M. C., Parel J. M.,
Behar-Cohen F. 2014. Evaluating in vivo delivery of riboflavin with
coulomb-controlled iontophoresis for corneal collagen
cross-linking: a pilot study. Invest Ophthalmol Vis Sci.
55:2731-2738. [0095] 30. Lim L. S., Mitchell P., Seddon J. M., Holz
F. G., Wong T. Y. Age-related macular degeneration. The Lancet.
379:1728-1738. [0096] 31. de Jong P. T. V. M. 2006. Age-Related
Macular Degeneration. New England Journal of Medicine.
355:1474-1485. [0097] 32. Jager R. D., Mieler W. F., Miller J. W.
2008. Age-Related Macular Degeneration. New England Journal of
Medicine. 358:2606-2617. [0098] 33. Irigoyen C., Ziahosseini K.,
Morphis G., Stappler T., Heimann H. 2012. Endophthalmitis following
intravitreal injections. Graefes Arch Clin Exp Ophthalmol.
250:499-505. [0099] 34. Ozawa Y., Sasaki M., Takahashi N.,
Kamoshita M., Miyake S., Tsubota K. 2012. Neuroprotective effects
of lutein in the retina. Curr Pharm Des. 18:51-56. [0100] 35.
Sasaki M., Ozawa Y., Kurihara T., Noda K., Imamura Y., Kobayashi
S., Ishida S., Tsubota K. 2009. Neuroprotective effect of an
antioxidant, lutein, during retinal inflammation. Invest Ophthalmol
Vis Sci. 50:1433-1439. [0101] 36. Woo T. T., Li S. Y., Lai W. W.,
Wong D., Lo A. C. 2013. Neuroprotective effects of lutein in a rat
model of retinal detachment. Graefes Arch Clin Exp Ophthalmol.
251:41-51. [0102] 37. Friedman D. S., O'Colmain B. J., Munoz B.,
Tomany S. C., McCarty C., de Jong P. T., Nemesure B., Mitchell P.,
Kempen J., Eye Diseases Prevalence Research G. 2004. Prevalence of
age-related macular degeneration in the United States. Arch
Ophthalmol. 122:564-572. [0103] 38. Eljarrat-Binstock E., Orucov
F., Aldouby Y., Frucht-Pery J., Domb A. J. 2008. Charged
nanoparticles delivery to the eye using hydrogel iontophoresis. J
Control Release. 126:156-161. [0104] 39. Gungor S., Delgado-Charro
M. B., Ruiz-Perez B., Schubert W., Isom P., Moslemy P., Patane M.
A., Guy R. H. 2010. Trans-scleral iontophoretic delivery of low
molecular weight therapeutics. J Control Release. 147:225-231.
[0105] 40. Pascolini D., Mariotti S. P., Pokharel G. P.,
Pararajasegaram R., Etya'ale D., Negrel A. D., Resnikoff S. 2004.
2002 global update of available data on visual impairment: a
compilation of population-based prevalence studies. Ophthalmic
Epidemiol. 11:67-115. [0106] 41. Congdon N., O'Colmain B., Klaver
C. C., Klein R., Munoz B., Friedman D. S., Kempen J., Taylor H. R.,
Mitchell P., Eye Diseases Prevalence Research G. 2004. Causes and
prevalence of visual impairment among adults in the United States.
Arch Ophthalmol. 122:477-485. [0107] 42. Seddon J. M., Ajani U. A.,
Sperduto R. D., Hiller R., Blair N., Burton T. C., Farber M. D.,
Gragoudas E. S., Haller J., Miller D. T., et al. 1994. Dietary
carotenoids, vitamins A, C, and E, and advanced age-related macular
degeneration. Eye Disease Case-Control Study Group. JAMA.
272:1413-1420. [0108] 43. van de Kraats J., Kanis M. J., Genders S.
W., van Norren D. 2008. Lutein and zeaxanthin measured separately
in the living human retina with fundus reflectometry. Invest
Ophthalmol Vis Sci. 49:5568-5573. [0109] 44. Barker F. M., 2nd,
Snodderly D. M., Johnson E. J., Schalch W., Koepcke W., Gerss J.,
Neuringer M. 2011. Nutritional manipulation of primate retinas, V:
effects of lutein, zeaxanthin, and n-3 fatty acids on retinal
sensitivity to blue-light-induced damage. Invest Ophthalmol Vis
Sci. 52:3934-3942. [0110] 45. Cunha-Vaz J., Bernardes R., Lobo C.
2011. Blood-retinal barrier. Eur J Ophthalmol. 21 Suppl 6:S3-9.
[0111] 46. Prausnitz M. R., Noonan J. S. 1998. Permeability of
cornea, sclera, and conjunctiva: a literature analysis for drug
delivery to the eye. J Pharm Sci. 87:1479-1488. [0112] 47.
www.jove.com/video/3765
* * * * *
References